Marotta Asset Management Sells 5,042 Shares of Astrazeneca Plc $AZN

Marotta Asset Management trimmed its position in shares of Astrazeneca Plc (NYSE:AZN) by 50.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 4,959 shares of the company’s stock after selling 5,042 shares during the quarter. Marotta Asset Management’s holdings in Astrazeneca were worth $995,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AZN. Natixis Advisors LLC raised its stake in shares of Astrazeneca by 14.3% in the third quarter. Natixis Advisors LLC now owns 2,100,390 shares of the company’s stock worth $161,142,000 after purchasing an additional 262,465 shares during the last quarter. Guardian Capital LP boosted its position in shares of Astrazeneca by 31.0% during the third quarter. Guardian Capital LP now owns 83,074 shares of the company’s stock valued at $6,373,000 after buying an additional 19,648 shares during the last quarter. Legacy Capital Group California Inc. bought a new stake in Astrazeneca in the 3rd quarter worth about $406,000. Focus Partners Advisor Solutions LLC increased its holdings in Astrazeneca by 53.8% in the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 10,307 shares of the company’s stock worth $875,000 after buying an additional 3,604 shares in the last quarter. Finally, Integral Health Asset Management LLC increased its holdings in Astrazeneca by 50.0% in the 3rd quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock worth $23,016,000 after buying an additional 100,000 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

Astrazeneca Stock Up 6.0%

Astrazeneca stock opened at $194.96 on Friday. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The stock has a fifty day moving average of $183.91 and a 200 day moving average of $187.76. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock has a market cap of $302.36 billion, a PE ratio of 29.27, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, sell-side analysts predict that Astrazeneca Plc will post 10.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday. Weiss Ratings lowered shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Bank of America reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Fourteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.